Lewis Richard A
From a private practice, Sacramento, California, USA.
J Cataract Refract Surg. 2014 Aug;40(8):1301-6. doi: 10.1016/j.jcrs.2014.01.032. Epub 2014 Jun 15.
This review considers a minimally invasive ab interno approach to glaucoma filtration surgery. Glaucoma filtration surgery can be defined as an attempt to lower intraocular pressure (IOP) by the surgical formation of an artificial drainage pathway from the anterior chamber to the subconjunctival space. Subconjunctival drainage of aqueous fluid has been a cornerstone of glaucoma surgery for more than a century. Varying techniques have been deployed to provide access to this space. Yet, despite numerous innovations in filtering surgery to achieve safe IOP reduction, too many short-term and long-term complications are associated with this surgery. This article describes the development of a new, soft, and permanent ab interno collagen implant (XEN gel stent) to optimize aqueous drainage to the subconjunctival space. Specific characteristics are critical in designing such an implant. Determining the optimum size of the device lumen to avoid hypotony while maximizing long-term outflow is crucial. Other topics discussed include material, length, diameter, flexibility, stability, and biocompatibility of the implant. Preclinical and human eye testing shows that the implant does not seem to occlude inside the lumen and the implant material does not appear to cause tissue reaction in the eye. The ab interno placement of the stent offers an alternative for lowering IOP with a minimally invasive procedure, minimum conjunctival tissue disruption, restricted flow to avoid hypotony, and long-term safety.
Dr. Lewis received financial support from Aquesys, Inc. as a consultant.
本综述探讨青光眼滤过手术的微创经内路方法。青光眼滤过手术可定义为通过手术建立从前房到结膜下间隙的人工引流通道来降低眼压(IOP)的尝试。房水的结膜下引流在一个多世纪以来一直是青光眼手术的基石。人们采用了各种技术来进入这个间隙。然而,尽管在滤过手术方面有众多创新以实现安全降低眼压,但该手术仍伴有太多短期和长期并发症。本文介绍了一种新型、柔软且永久性的经内路胶原蛋白植入物(XEN凝胶支架)的研发,以优化房水向结膜下间隙的引流。在设计这样一种植入物时,特定特征至关重要。确定装置管腔的最佳尺寸以避免低眼压同时使长期房水流出最大化至关重要。讨论的其他主题包括植入物的材料、长度、直径、柔韧性、稳定性和生物相容性。临床前和人体眼部测试表明,该植入物在管腔内似乎不会堵塞,且植入材料在眼中似乎不会引起组织反应。支架的经内路放置为通过微创程序降低眼压提供了一种选择,可使结膜组织破坏最小化、限制房水流动以避免低眼压并确保长期安全性。
刘易斯博士作为顾问接受了Aquesys公司的资金支持。